United States of America based
Founded in 2016, by Nathan Magarvey, PhD, Chief Scientific Officer, Adapsyn is developing a bioinformatics platform devoted to discovering previously unidentified natural product drug candidates by selectively isolating new agents with the potential to interrogate difficult-to-drug phenotypes. The company applies proprietary machine learning to genomic and metabolomic data from microbes to discover new natural products encoded within microbial genomes.
Adapsyn has ongoing collaborations with leading pharmaceutical companies and is actively developing an internal pipeline of therapeutic candidates.
Adapsyn’s platform analyses metabolomic and genomic data to identify, isolate, and assay novel drug-like small molecules from bacteria.
No pipelines published yet
No services posted yet